OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report released on Tuesday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and set a $4.25 target price on shares of OncoCyte in a research report on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $4.06.

OncoCyte Price Performance

Shares of OncoCyte stock opened at $3.11 on Tuesday. The company’s fifty day moving average price is $3.07 and its two-hundred day moving average price is $2.94. OncoCyte has a 52-week low of $2.08 and a 52-week high of $4.34.

OncoCyte (NASDAQ:OCX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. The business had revenue of $0.10 million during the quarter. OncoCyte had a negative net margin of 3,558.46% and a negative return on equity of 149.88%.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The shares were bought at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Andrea S. James bought 33,670 shares of OncoCyte stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now directly owns 33,670 shares in the company, valued at approximately $99,999.90. The disclosure for this purchase can be found here. Corporate insiders own 1.94% of the company’s stock.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.